ArticleBrain, behavior, and immunity2025
C-reactive protein as a possible indicator of PTSD prognosis and comorbid anhedonia.
Article in Brain, behavior, and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study.Frontiers in neuroscience · 2026Article
- PACAP a mediator of inflammation following trauma exposure and mild traumatic brain injury: Differential effects in males and females.Brain, behavior, and immunity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Posttraumatic stress disorder (PTSD) is often chronic, which is costly to the individual and society. Easy-to-measure prognostic indicators can help to ensure that those with the greatest symptoms receive treatment. Inflammatory biomarkers may precede and predict depression chronicity and worsening, as well as PTSD. Yet, it is unknown if inflammatory biomarkers predict changes in symptoms among those who have already developed PTSD. Among 82 US military veterans (82 % male) diagnosed with PTSD, we measured C-reactive protein (CRP) and conducted clinical diagnostic interviews assessing PTSD and major depression at two visits, an average of five years apart. Cross-lagged models revealed that CRP at Time 1 was positively associated with PTSD symptom severity (p = 0.017), depression diagnosis (p < 0.001), depressive symptom count (p=.001), and anhedonia (p < 0.001) but not low mood (p = 0.183) at Time 2, covarying for baseline levels of these outcomes as autoregressive effects and for potential confounds. Results suggest that elevated CRP may be a risk factor for more chronic and severe PTSD symptoms, perhaps with comorbid anhedonic depression. Further exploration of CRP as a prognostic indicator of PTSD is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.